April 22, 2024

TREFFpunkt Gesundheitsindustrie: Mensch. Maschine. Miteinander? KI & Robotik in der Medizin

TREFFpunkt Gesundheitsindustrie: Mensch. Maschine. Miteinander? KI & Robotik in der Medizin
Go back

TREFFpunkt Gesundheitsindustrie 2026 | Mensch. Maschine. Miteinander? KI & Robotik in der Medizin

Automatisierung, Robotik und Künstliche Intelligenz (KI) sind Motoren fürInnovation, Effizienz und Versorgungssicherheit im Gesundheitswesen. Ob akuter Fachkräftemangel, demographischer Wandel oder steigender Kostendruck – als Schlüsseltechnologien haben sie das Potenzial, zentrale Herausforderungen unserer Zeit zu bewältigen. Durch optimiertes Datenmanagement, effiziente Ressourcenplanung, KI-gestützte Diagnostik und Therapie, Robotik sowie smarte Assistenten versprechen Automatisierung und KI wirkungsvolle Lösungen und Entlastung.

Der TREFFpunkt Gesundheitsindustrie bringt Entscheider, Vordenkerinnen und Innovatoren aus Unternehmen und Start-ups, Forschung und Versorgung zusammen, um Automatisierung, Robotik und KI zu beleuchten, disruptive Technologien live zu erleben und gemeinsam Lösungen für die Zukunft der Branch ezu diskutieren.

Wann: 19. März 2026
Wo: Hospitalhof Stuttgart

Hier geht’s zum Programm: www.treffpunkt-gesundheitsindustrie.de/programm
Jetzt kostenfrei anmelden unter www.treffpunkt-gesundheitsindustrie.de/anmeldung!

Organisiert wird das Event von der Landesagentur BIOPRO Baden-Württemberg GmbH. Gemeinsam mit dem Regionalpartner 2026, der BioRegio STERN Management GmbH, macht sie Innovationen aus THE LÄND sichtbar.

register now

Our latest News

discover more
Member2Member: Where expertise meets the community

Member2Member: Where expertise meets the community

Every company in the bioRN network has a story to tell. More importantly, every company has knowledge that can help others move faster, avoid mistakes and spark new collaborations. That is the idea behind bioRN’s Member2Member series. Instead of traditional company presentations, Member2Member opens the doors to our member organisations and puts their expertise centre […]

read more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

read more
Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp